
Oscar Health (OSCR) Stock Forecast & Price Target
Oscar Health (OSCR) Analyst Ratings
Bulls say
Oscar Health Inc. reported a revenue of $2.86 billion for 2Q25, marking a 29.0% year-over-year increase, driven by strong member retention and growth from special enrollment periods (SEPs). The company's medical loss ratio (MLR) stood at 91.1%, which, despite being above consensus estimates, reflects an improvement of 1200 basis points year-over-year and 1560 basis points sequentially, positioning Oscar Health favorably despite increased market morbidity. Additionally, management anticipates an uptick in utilization in 4Q25, suggesting a proactive approach to managing future growth and operational efficiency.
Bears say
Oscar Health Inc. reported a significant operating loss of $230.5 million in the second quarter of 2025, which aligns with prior announcements but reinforces concerns about the company's financial performance. Additionally, the adjusted EBITDA of negative $199.4 million fell short of consensus estimates, indicating ongoing challenges in cost management and profitability. Furthermore, management's forecast of a modest decline in individual membership by year-end signals potential difficulties in customer retention and growth, further contributing to a negative outlook on the company's financial health.
This aggregate rating is based on analysts' research of Oscar Health and is not a guaranteed prediction by Public.com or investment advice.
Oscar Health (OSCR) Analyst Forecast & Price Prediction
Start investing in Oscar Health (OSCR)
Order type
Buy in
Order amount
Est. shares
0 shares